Literature DB >> 19262541

Acid inhibition and infections outside the gastrointestinal tract.

Nimish Vakil1.   

Abstract

Acid-inhibitory agents can alter the flora of the stomach, and epidemiologic studies suggest an association between the use of these agents and the development of pneumonia. Microbiologic studies suggest that a causal association may be biologically plausible because gastric colonization with organisms can occur in patients taking acid suppressive agents. In mechanically ventilated patients, colonization of the oropharynx and stomach may predispose to Gram-negative pneumonias. Despite the associations between acid inhibitor use and pneumonia shown in some studies, the data on community-acquired pneumonias are not conclusive. In clinical practice, prudence would dictate that the need for acid inhibition with histamine-2 receptor antagonists or proton pump inhibitors should be carefully considered in patients who are at risk for pneumonias (elderly patients with chronic lung disease who are on immunosuppressive drugs or corticosteroids and patients with recurrent lung infections requiring frequent antibiotic therapy).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19262541     DOI: 10.1038/ajg.2009.47

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

Review 1.  The risks of PPI therapy.

Authors:  Paul Moayyedi; Grigorios I Leontiadis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-14       Impact factor: 46.802

2.  Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice.

Authors:  Patrick S Yachimski; Elizabeth A Farrell; Daniel P Hunt; Andrea E Reid
Journal:  Arch Intern Med       Date:  2010-05-10

Review 3.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

4.  Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.

Authors:  John J Lima; Jason E Lang; Edward B Mougey; Kathryn B Blake; Yan Gong; Janet T Holbrook; Robert A Wise; W G Teague
Journal:  J Pediatr       Date:  2013-04-24       Impact factor: 4.406

Review 5.  Prescribing proton pump inhibitors: is it time to pause and rethink?

Authors:  Nimish Vakil
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

6.  Inhibition of Gastric Acid Secretion by H2 Receptor Antagonists Associates a Definite Risk of Enteric Peritonitis and Infectious Mortality in Patients Treated with Peritoneal Dialysis.

Authors:  Miguel Pérez-Fontan; Daniela Machado Lopes; Alba García Enríquez; Beatriz López-Calviño; Andrés López-Muñiz; Teresa García Falcón; Ana Rodríguez-Carmona
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

Review 7.  Widespread use of gastric acid inhibitors in infants: Are they needed? Are they safe?

Authors:  Mark Safe; Wei H Chan; Steven T Leach; Lee Sutton; Kei Lui; Usha Krishnan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-11-06

8.  Risk of pneumonia in patients with gastroesophageal reflux disease: A population-based cohort study.

Authors:  Wan-Tseng Hsu; Chih-Cheng Lai; Ya-Hui Wang; Ping-Huei Tseng; Kun Wang; Cheng-Yi Wang; Likwang Chen
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

9.  Acid suppressive agents and risk of Mycobacterium tuberculosis: case-control study.

Authors:  Wen-Hung Hsu; Chao-Hung Kuo; Sophie S W Wang; Chien-Yu Lu; Chung-Jung Liu; Seng-Kee Chuah; Fu-Chen Kuo; Yen-Hsu Chen; Yaw-Bin Huang; Ming-Feng Hou; Deng-Chyang Wu; Huang-Ming Hu
Journal:  BMC Gastroenterol       Date:  2014-05-13       Impact factor: 3.067

10.  Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan.

Authors:  Kao-Chi Cheng; Kuan-Fu Liao; Cheng-Li Lin; Shih-Wei Lai
Journal:  Front Pharmacol       Date:  2017-07-19       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.